Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.57) by 4.46 percent. This is a 6.83 percent increase over losses of $(1.61) per share from the same period last year.
UBS Downgrades Amedisys to Sell, Lowers Price Target to $95
UBS analyst Andrew Mok downgrades Amedisys (NASDAQ:AMED) from Neutral to Sell and lowers the price target from $145 to $95.
